Clenbuterol

ID: clenbuterol

Aliases: clen, clenbuterol hydrochloride

Type: compound

Route/form: oral in many PED contexts; approved human route varies by country and it is not approved for human use in the US

Status: not_approved_for_human_use_in_us

Evidence level: early human

Best data tier: early human + human controlled/review + case-report/safety

Support scope: human, review/regulatory

Source types: case_report, early_human, human_rct, human_trial, review, systematic_review

Linked sources: 6

Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• beta-2 adrenergic receptor agonist
• bronchodilation
• skeletal-muscle beta-2 signaling
• thermogenesis/lipolysis hypotheses

Optimization domains

• fat loss
• exercise performance
• muscle
• stimulant
• cardiovascular
• doping

Research basis

• Human clenbuterol physiology data support beta-2 effects on lean mass and muscle protein accretion, but the best recent trial also reported attenuated cardiorespiratory fitness and beta2-desensitization.
• Beta-2 agonist biology makes fat-loss/performance interest coherent, and disease-context human data provide a limited muscle-function signal.
• It is important to include because it is widely discussed as a PED/fat-loss stimulant, not because the risk-benefit case is favorable.

Limits, risks, and missing evidence

• The safety margin is poor in misuse contexts, with tachycardia, tremor, hypokalemia, arrhythmias, anxiety-like symptoms, overdose reports, and athlete adverse-event case literature.
• Lean mass or protein-accretion signals do not equal better endurance, safer fat loss, or sustainable performance.
• US human-use status, dose escalation, stacking with stimulants/thyroid drugs, and cardiovascular baseline risk are central.

Risk flags

• not us approved for human use
• stimulant cardiovascular risk
• arrhythmia risk
• hypokalemia
• doping
• narrow safety margin

Linked papers, labels, and reviews

1. Skeletal muscle beta2-adrenoceptor density and muscle strength and hypertrophy response to beta2-agonist treatment with clenbuterol
   human_trial / pubmed_clenbuterol_healthy_men_2019
   Human clenbuterol physiology/training source in healthy men; relevant to beta-2 anabolic/performance claims but still safety-limited.
2. Clenbuterol as a Substance of Abuse
   review / pubmed_clenbuterol_toxicity_review_2020
   Abuse/toxicity review; anchors tachycardia, hypokalemia, tremor, arrhythmia, and overdose-risk framing.
3. Adverse events from clenbuterol misuse
   case_report / pubmed_clenbuterol_adverse_events_2013
   Poison-center/case-series style safety source for clenbuterol misuse presentations.
4. Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle beta2-adrenergic signalling
   human_rct / pubmed_clenbuterol_lean_mass_protein_2025
   Healthy-men trial with oral clenbuterol cycles; supports lean-mass/protein-accretion signal while documenting fitness and beta2-desensitization tradeoffs.
5. Adverse events of clenbuterol among athletes: a systematic review of case reports and case series
   systematic_review / pubmed_clenbuterol_athlete_adverse_events_2023
   Athlete adverse-event synthesis for clenbuterol misuse; central risk source for PED/fat-loss framing.
6. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy
   early_human / pubmed_clenbuterol_sbma_pilot_2013
   Small disease-context human trial; relevant to beta2-muscle rationale but not healthy fat-loss or bodybuilding evidence.